Literature DB >> 9872479

Coexistent minocycline-induced systemic lupus erythematosus and autoimmune hepatitis.

J M Angulo1, L H Sigal, L R Espinoza.   

Abstract

OBJECTIVES: This study was performed to raise awareness among rheumatologists about two autoimmune disorders associated with long-term minocycline therapy that can coexist in the same patient. We provide an update on the occurrence of these disorders, their main characteristics, and the current knowledge of potential pathogenic mechanisms.
METHODS: We searched the medical literature in English indexed in MEDLINE from 1966 through April 1998 for the term minocycline combined with each of the following: autoimmune hepatitis (AIH), chronic hepatitis, lupus, systemic lupus erythematosus (SLE), anti-myeloperoxidase (anti-MPO), arthritis, vasculitis, and toxicity. We also reviewed relevant references cited in the articles our search uncovered.
RESULTS: We identified over 60 minocycline-induced cases of SLE and 24 cases of minocycline-induced AIH. Both autoimmune disorders coexisted in the same patient in 12 cases reported in the literature and in one case seen at our clinic. These 13 patients were characterized by symmetrical polyarthralgias/polyarthritis, elevated liver enzymes, and positive antinuclear antibodies (ANA); they also were generally anti-histone-negative, and only two patients had perinuclear anti-neutrophil cytoplasmic antibodies (p-ANCA). After withdrawal of minocycline, their symptoms resolved, and abnormal laboratory results normalized or markedly improved.
CONCLUSIONS: Although data on the actual prevalence of autoimmune disorders induced by minocycline are not available, numerous case reports or small series deal with such disorders. Probable pathogenic mechanisms for each of these conditions are discussed.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9872479     DOI: 10.1016/s0049-0172(98)80035-8

Source DB:  PubMed          Journal:  Semin Arthritis Rheum        ISSN: 0049-0172            Impact factor:   5.532


  7 in total

1.  Etiological role of brucellosis in autoimmune hepatitis.

Authors:  Colakoglu Onder; Taskiran Bengur; Adnan Kirci; Tunakan Mine; Buyrac Zafer; Unsal Belkis; Aksoz Kadir; Yorukoglu Gazi
Journal:  World J Gastroenterol       Date:  2005-04-14       Impact factor: 5.742

2.  Liver damage associated with minocycline use in acne: a systematic review of the published literature and pharmacovigilance data.

Authors:  R A Lawrenson; H E Seaman; A Sundström; T J Williams; R D Farmer
Journal:  Drug Saf       Date:  2000-10       Impact factor: 5.606

Review 3.  Minocycline for acne vulgaris: efficacy and safety.

Authors:  Sarah E Garner; Anne Eady; Cathy Bennett; John Norman Newton; Karen Thomas; Catalin Mihai Popescu
Journal:  Cochrane Database Syst Rev       Date:  2012-08-15

4.  Antimitochondrial antibody heterogeneity and the xenobiotic etiology of primary biliary cirrhosis.

Authors:  Richy C Y Chen; Phornnop Naiyanetr; Shang-An Shu; Jinjun Wang; Guo-Xiang Yang; Thomas P Kenny; Kathryn C Guggenheim; Jeffrey D Butler; Christopher Bowlus; Mi-Hua Tao; Mark J Kurth; Aftab A Ansari; Marshall Kaplan; Ross L Coppel; Ana Lleo; M Eric Gershwin; Patrick S C Leung
Journal:  Hepatology       Date:  2013-01-29       Impact factor: 17.425

5.  Minocycline Reduces Chemoradiation-Related Symptom Burden in Patients with Non-Small Cell Lung Cancer: A Phase 2 Randomized Trial.

Authors:  Xin Shelley Wang; Qiuling Shi; Tito Mendoza; Steven Lin; Joe Y Chang; Raza H Bokhari; Hui-Kai Lin; Araceli Garcia-Gonzalez; Mona Kamal; Charles S Cleeland; Zhongxing Liao
Journal:  Int J Radiat Oncol Biol Phys       Date:  2019-10-15       Impact factor: 7.038

6.  Nanoliposomal minocycline for ocular drug delivery.

Authors:  James M Kaiser; Hisanori Imai; Jeremy K Haakenson; Robert M Brucklacher; Todd E Fox; Sriram S Shanmugavelandy; Kellee A Unrath; Michelle M Pedersen; Pingqi Dai; Willard M Freeman; Sarah K Bronson; Thomas W Gardner; Mark Kester
Journal:  Nanomedicine       Date:  2012-03-28       Impact factor: 5.307

7.  [Cutaneous xanthomas associated with minocycline-induced cholestatic jaundice].

Authors:  C Bamberg; J Laskowski; R Zimmermann; G Gross
Journal:  Hautarzt       Date:  2003-09       Impact factor: 1.198

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.